Clinical Trial: Comparative Efficacy of Once-daily LAMA/LABA Combinations Versus Tiotropium on Constant-work-rate Cycle Endurance in COPD

U.S., April 22 -- ClinicalTrials.gov registry received information related to the study (NCT07541378) titled 'Comparative Efficacy of Once-daily LAMA/LABA Combinations Versus Tiotropium on Constant-work-rate Cycle Endurance in COPD' on April 07.

Brief Summary: This study is designed to directly compare the effects of widely available long-acting bronchodilator therapies in patients with chronic obstructive pulmonary disease (COPD). The trial evaluates three fixed-dose combinations of a long-acting beta-2 agonist and a long-acting muscarinic antagonist (LABA/uLAMA)-umeclidinium/vilanterol (Anoro(R) Ellipta), indacaterol/glycopyrronium (Ultibro(R) Breezhaler), and tiotropium/olodaterol (Spiolto(R) Respimat)-against tiotropium (Spiriva(R)), a...